Lynx1 Capital Management LP Has $46.25 Million Holdings in GH Research PLC (NASDAQ:GHRS)

Lynx1 Capital Management LP raised its holdings in GH Research PLC (NASDAQ:GHRS - Free Report) by 19.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,966,726 shares of the company's stock after buying an additional 656,163 shares during the quarter. GH Research accounts for approximately 16.7% of Lynx1 Capital Management LP's holdings, making the stock its 3rd biggest holding. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. AdvisorShares Investments LLC boosted its stake in shares of GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company's stock valued at $280,000 after purchasing an additional 1,977 shares in the last quarter. BVF Inc. IL boosted its stake in shares of GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company's stock valued at $60,321,000 after purchasing an additional 1,125,000 shares in the last quarter. Finally, RA Capital Management L.P. boosted its stake in shares of GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company's stock valued at $66,643,000 after purchasing an additional 664,381 shares in the last quarter. Institutional investors own 56.90% of the company's stock.

GH Research Trading Down 1.7 %

NASDAQ GHRS traded down $0.12 on Friday, hitting $6.88. 74,857 shares of the company were exchanged, compared to its average volume of 82,060. The firm has a 50 day moving average of $9.94 and a two-hundred day moving average of $11.13. The company has a market cap of $357.95 million, a P/E ratio of -11.10 and a beta of 0.83. GH Research PLC has a 1-year low of $5.05 and a 1-year high of $14.99.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. Research analysts anticipate that GH Research PLC will post -0.89 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reiterated a "market outperform" rating and set a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).